Evidence map›Paper›PMID 32221983›Full record

ReviewJournal of medical virology2020

Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.

Hao Cheng, Yan Wang, Gui-Qiang Wang

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of medical virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 275 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
275citing papers in PubMed, 8 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

275 citing papers in PubMed, 8 syntheses or guidelines pooled it, 562 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

215 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hao ChengDepartment of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.ORCID 0000-0003-2630-614X
Yan WangDepartment of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.ORCID 0000-0002-8577-0527
Gui-Qiang WangDepartment of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.ORCID 0000-0003-0515-7974
Peking University · CN

Funding

13th Five-Year National Science and Technology Major Project 2017ZX1020320213th Five-Year National Science and Technology Major Project 2018ZX10302206-001-007National Natural Science Foundation of China 81870417
6 · The paper itself

Abstract

This article reviews the correlation between angiotensin-converting enzyme 2 (ACE2) and severe risk factors for coronavirus disease 2019 (COVID-19) and the possible mechanisms. ACE2 is a crucial component of the renin-angiotensin system (RAS). The classical RAS ACE-Ang II-AT1R regulatory axis and the ACE2-Ang 1-7-MasR counter-regulatory axis play an essential role in maintaining homeostasis in humans. ACE2 is widely distributed in the heart, kidneys, lungs, and testes. ACE2 antagonizes the activation of the classical RAS system and protects against organ damage, protecting against hypertension, diabetes, and cardiovascular disease. Similar to SARS-CoV, SARS-CoV-2 also uses the ACE2 receptor to invade human alveolar epithelial cells. Acute respiratory distress syndrome (ARDS) is a clinical high-mortality disease, and ACE2 has a protective effect on this type of acute lung injury. Current research shows that the poor prognosis of patients with COVID-19 is related to factors such as sex (male), age (>60 years), underlying diseases (hypertension, diabetes, and cardiovascular disease), secondary ARDS, and other relevant factors. Because of these protective effects of ACE2 on chronic underlying diseases and ARDS, the development of spike protein-based vaccine and drugs enhancing ACE2 activity may become one of the most promising approaches for the treatment of COVID-19 in the future.

Indexed as

PandemicsAge FactorsAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAngiotensin IAntiviral AgentsBetacoronavirusCardiovascular DiseasesCoronavirus InfectionsCOVID-19Gene Expression RegulationHost-Pathogen InteractionsHumansPeptide FragmentsPeptidyl-Dipeptidase APneumonia, ViralACE2 protein, humanAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAngiotensin Iangiotensin I (1-7)Antiviral AgentsMAS1 protein, humanPeptide FragmentsPeptidyl-Dipeptidase AProto-Oncogene MasReceptor, Angiotensin, Type 1Receptors, VirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2acute respiratory distress syndrome (ARDS)angiotensin-converting enzyme 2 (ACE2)coronavirus disease 2019 (COVID-19)renin-angiotensin system (RAS)severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Identifiers

PMID32221983
PMCPMC7317908
OpenAlexW3013694216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.